Beltsville, MD, and Philadelphia, PA, January 26, 2010 – BioServe and Fox Chase Cancer Center today announced the formation of an exclusive strategic alliance aimed at easing a bottleneck in oncology research programs. Through this agreement, BioServe will supplement biomaterial from its Global Repository with samples from the prestigious Fox Chase Cancer Center, giving researchers access to an even larger and more dynamic repository of clinical-grade biospecimens.
A shortage of clinical quality biomaterials in cancer, sufficient to power large-scale genetic and biomarker studies, has created this bottleneck in biotech research.
“BioServe’s alliance with Fox Chase creates an opportunity to accelerate discoveries in oncology, the most robust and largest segment of pre-clinical biomarker and drug development programs,” said Rama Modali, President of BioServe. “The scope and sustainability of specimens collected by Fox Chase is as unique as it is impressive, covering nearly every major solid tumor type.”
Internationally renowned for cancer research and treatment, Fox Chase also serves as the center of a comprehensive patient care network covering the densely populated three-state region surrounding Philadelphia. As a result, tissue and blood specimens collected for the repository can trace each anonymized patient’s pathway from pre-diagnosis to treatment and through long-term follow up care. Fox Chase specimens collected at each stage are supported by annotations that include medical histories, detailed records of treatment protocols as well as outcomes.
“Our biosamples have tremendous clinical value, and getting them into the hands of as many cancer researchers as possible is a priority for us,” said Jeff Boyd, Ph.D., Chief Scientific Officer and Senior Vice President at Fox Chase Cancer Center. “We know that making our biosamples available to the wider scientific community will accelerate the pace of cancer research. With this goal in mind, partnering with BioServe makes a lot of sense for us.
As a leader in biomaterial collection and distribution, BioServe is substantively engaged with cancer research being conducted by pharma, biotech and leading academic research institutions worldwide.
BioServe’s alliance with Fox Chase for distribution of biospecimens spans 2 years, assuring a stable and renewable source of biosamples for ongoing and concurrent research programs.
“This is not a static repository,” added Modali. “There is a capability to fulfill standing requests for specimens, as well as a flexibility to meet emerging needs as research programs define targets or pursue promising new directions.”